IMT is a private early-stage biotechnology startup based in Sydney Australia that focuses on the clinical & commercial development of a humanized anti-IgD monoclonal antibody (mAb).
Therapeutic anti-IgD mAb is designed and developed as a first-in-class, disease-modifying mAb drug for human autoimmune diseases, allergic and chronic inflammation, and potentially other human immune-mediated conditions including graft versus host diseases (cGVHD) in bone marrow transplantation, organ transplant rejections, and neurodegenerative Parkinson’s and Alzheimer’s diseases.
IMT was founded by Dr. Tue (Tommie) Gia Nguyen, a senior biomedical research fellow with over 15 years of experience in molecular & cancer cell biology, immunology, and biotechnology. His postdoctoral research demonstrated the novel therapeutic effects of anti-IgD mAb in animal models of autoimmune diseases and allergic skin inflammations. He has received a number of scientific prizes, awards, and research grants for this research works. Dr Nguyen is the leading inventor and senior author on granted patents on anti-IgD mAb and its related research publications. His scientific publications and research profile can be found on Google Scholar, Research Gate or LinkedIn. For research publications and corroborating independent studies related to therapeutic anti-IgD mAb, see IMT Research Publications page.
IMT is currently raising capitals to produce a humanized anti-IgD mAb prototype with the aim to advance this novel and paradigm-shifting therapeutic mAb drug to human clinical trials. For inquiries regarding IMT investment/partnership opportunities, please contact IMT.
Anti-IgD mAb is a first-in-classe, disease-modifying therapeutic monoclonal antibody (mAb) biologic designed to bind immunoglobulin D (IgD) to activate and engage the body’s intrinsic immune tolerance mechanisms and anti-inflammatory regulatory feedback responses to target the root causes of human autoimmune diseases and allergies.
Autoimmune diseases and allergic conditions affect approximately 2-15% of the global population, with rising prevalences, substantial healthcare burdens and significant socio-economic impacts amounting hundreds of billion dollars annually (Miller FW, Curr. Opin. Immunol., 2023). Despite considerable advances in treatments using monoclonal antibody drugs, about 10-50% of patients fail to response adequately to the existing antibody drugs and immunosuppressants, which also cause a blanketed immunosuppression. This clinical challenge represents a significant unmet patient need and underscores the demand for more effective therapeutics for patients with refractory autoimmune diseases, allergies and immune-mediated conditions.
The current therapeutic paradigm and treatment strategies for human autoimmune diseases and allergies primarily focus on suppressing the body’s immune responses by blocking pro-inflammatory cytokines and pathways to reduce inflammation. These immunosuppressants do not induce or activate the body’s natural immune tolerance mechanisms to address the key underlying cause of human autoimmune diseases and allergies.
In contrast to the current mAb drugs, anti-IgD mAb is designed to activate rather than suppress the immune responses to induce and engage the body’s inbuilt immune tolerogenic and anti-inflammatory responses to alleviate autoimmune diseases and allergic conditions. Anti-IgD mAb works as both a selective B-cell depleting and immunomodulating mAb to restore the balance of immune tolerance and pro-inflammatory responses in chronic inflammatory conditions to achieve long last therapeutic effects with minimal compromises to the body’s protective immune responses against infections (Nguyen TG, Int. Rev. Immunol., 2022).
IgD Mab Technology (IMT) 